Diabetes Care Devices Market - Segmented by Product and Geography - Growth, Trends, and Forecast (2019 - 2024)

+1 617-765-2493

GLOBAL DIABETES CARE DEVICES MARKET (2012- 2024)

The market is segmented by product type Management Devices (Insulin Pumps, Insulin Pens, Syringes, cartridges and Jet Injectors) and Monitoring Devices (Self-monitoring Blood Glucose (Hospital and Personal use) and Continuous Glucose Monitoring) and geography.

PURCHASE REPORT
DCD intro

Study Period:

2012-2024

Base Year:

2019

Fastest Growing Market:

North America

Largest Market:

North America

Key Players:

PURCHASE REPORT

Market Overview

  • The Global Diabetes Care Devices market is expected to register a CAGR of about 6.8% during the forecast period (2019-2023).
  • Asia-Pacific is anticipated to dominate the market during the forecast period, owing to rising prevalence of obesity in the region.
  • There has been significant rise in Insulin delivery systems technology from Insulin Injections to Insulin pumps. 
  • Technological innovations and advances give much convenience in measuring the blood glucose levels, one such advancement in monitoring the blood glucose levels is established with Continuous glucose monitoring devices.  

Scope of the Report

The market is segmented by product type Management Devices (Insulin Pumps, Insulin Pens, Syringes, cartridges and Jet Injectors) and Monitoring Devices (Self-monitoring Blood Glucose (Hospital and Personal use) and Continuous Glucose Monitoring) and geography.

By Monitoring Devices Self-Monitoring Blood Glucose Glucometer Devices Hospital
Personal
Blood Glucose Test Strips
Lancets
Continous Glucose Monitoring Sensors  
Receivers  
By Management Devices Insulin Pump Insulin Pump Device  
Insulin Pump Reservoir  
Infusion Set  
Syringes Syringes  
Cartridges Cartridges  
Disposable Pens Disposable Pens  
Jet Injectors Jet Injectors  
By Region North America Canada  
Rest of North America  
United States  
Europe United Kingdom  
Germany  
France  
Russia  
Spain  
Italy  
Rest of the Europe  
Asia Pacific Australia  
China  
India  
Indonesia  
Japan  
Malaysia  
Philippines  
Rest of Asia Pacific  
South Korea  
Thailand  
Vietnam  
Latin America Brazil  
Mexico  
Rest of Latin America  
Middle East & Africa Saudi Arabia  
South Africa  
Iran  
Rest of Middle East & Africa  
Egypt  
Oman  

Key Market Trends

Rising Prevalence of Diabetes

  • As per a WHO report, the global prevalence of diabetes among adults of over 18 years has accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.
  • Diabetes prevalence has been rising rapidly in the middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.
  • Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO projects that diabetes is likely to be the seventh leading cause of death by 2030.
  • Growing prevalence of diabetes is the major driver for the global diabetes care devices market. Additionally, rising awareness regarding diabetes care, growing prevalence of obesity, and technological advancements are further driving the market for diabetes care devices.
DCD rev

North America to Dominate the Monitoring Devices Market

  • The factors attributing to this growth are the rising prevalence of diabetes, caused mainly due to urbanization and sedentary lifestyles.  
  • Asia-Pacific is anticipated to grow tremendously during the forecast period, owing to factors, such as a high prevalence of diabetes, growing obese population, and government initiatives of raising awareness, regarding diabetic care.
Picture1

Competitive Landscape

There have been constant innovations driven by manufacturers to compete and struggle in the market. The major players such as Abbott, Medtronic, etc. resort to inorganic market strategies such as mergers and acquisitions to establish market dominance while also adhering to organic growth strategies, which is evident from the R&D spending of these companies. Examples of a few strategic outcomes include:

  • In March 2018, Medtronic PLC received the US Food and Drug Administration (FDA) approval for Guardian(TM) Connect continuous glucose monitoring (CGM) system, for diabetics aged between aged between 14-75 years.
  • In January 2018, Abbott announced that the FreeStyleLibre System, the company's revolutionary new continuous glucose monitoring (CGM) system, is now available to Medicare patients in the United States.

Major Players

  1. Abbott
  2. Dexcom
  3. Roche
  4. Becton Dickinson and Company
  5. Medtronic

* Complete list of players covered available in the table of contents below

DCD csa

Customize the Report

80% of our clients ask for some sort of customisation, be it specific countries / companies / segments.

What are you looking for?

Please Enter a Valid Email ID!

Please Enter a Valid Message!

Table of Contents

  1. INTRODUCTION
    1. Study Deliverables
    2. Study Assumptions
    3. Scope of the Study
  2. RESEARCH METHODOLOGY
  3. EXECUTIVE SUMMARY
  4. MARKET DYNAMICS
    1. Market Overview
    2. Drivers
    3. Restraints
    4. Porter's Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Intensity of Competitive Rivalry
  5. Market Segmentation
    1. Monitoring Devices
      1. Self-Monitoring Blood Glucose Devices
        1. By Component (Value and Volume, 2012 - 2024)
          1. Glucometer Devices
          2. Test Strips
          3. Lancets
        2. By End User
          1. Hospital (Value and Volume, 2012 - 2024)
            1. Glucometer Devices
            2. Test Strips
            3. Lancets
          2. Personal (Value and Volume, 2012 - 2024)
            1. Glucometer Devices
            2. Test Strips
            3. Lancets
      2. Continuous Blood Glucose Monitoring
        1. By Component (Value and Volume, 2012 - 2024)
          1. Sensors
          2. Receivers
    2. Management Devices
      1. Insulin Pump
        1. Insulin Pump Device
        2. Insulin Pump Reservoir
        3. Infusion Set
      2. Insulin Syringes
      3. Insulin Cartridges
      4. Disposable Pens
      5. Jet Injectors
    3. Geography
      1. North America
        1. United States (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        2. Canada (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        3. Rest of North America (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      2. Europe
        1. France (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        2. Germany (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        3. Italy (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        4. Spain (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        5. United Kingdom (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        6. Russia (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        7. Rest of Europe (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      3. Latin America
        1. Mexico (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        2. Brazil (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        3. Rest of Latin America (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      4. Asia-Pacific
        1. Japan (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        2. South Korea (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        3. China (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        4. India (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        5. Australia (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        6. Vietnam (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        7. Malaysia (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        8. Indonesia (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        9. Philippines (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        10. Thailand (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        11. Rest of Asia Pacific (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      5. Middle East and Africa
        1. Saudi Arabia (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        2. Iran (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        3. Egypt (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        4. Oman (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        5. South Africa (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
        6. Rest of Middle and Africa (Value and Volume, 2012 - 2024)
          1. By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
          2. By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
          3. By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
  6. MARKET INDICATORS
    1. Type-1 Diabetes population (2012-2024)
    2. Type-2 Diabetes population (2012-2024)
  7. COMPETITIVE LANDSCAPE
    1. COMPANY PROFILES
      1. Abbott Diabetes Care
      2. Roche
      3. Johnson & Johnson
      4. Dexcom
      5. Medtronic
      6. Arkray
      7. Ascensia Diabetes Care
      8. Agamatrix Inc.
      9. Bionime Corporation
      10. Acon
      11. Medisana
      12. Trivida
      13. Rossmax
    2. COMPANY SHARE ANALYSIS
      1. Roche
      2. Johnson & Johnson
      3. Abbott Diabetes Care
      4. Dexcom
      5. Medtronics
      6. Novo Nordisk
      7. Eli Lilly
      8. Sanofi
      9. Others
  8. MARKET OPPORTUNITIES AND FUTURE TRENDS
mordor logo gray
Mordor Intelligence Copyright © 2016 . All Rights Reserved.